Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790793 | 0.80 | NPC1 (0.59) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL25045602 | 0.78 | APP (0.49) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL24320031 | 0.76 | NPC1 (0.74) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL433724 | 0.75 | RAB9A (0.56) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL14427902 | 0.75 | CYP11B1 (0.57) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2242841 | 0.75 | NPC1 (0.40) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL3138257 | 0.75 | PIK3CG (0.60) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL13391848 | 0.75 | APP (0.42) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2294229 | 0.75 | APP (0.50) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL418021 | 0.75 | PIK3CG (0.60) | APPNPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112469707-B | Preventive or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023104209-A1 | METTL3 INHIBITOR COMPOUND | 上海昂阔医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2014055955-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | disclosed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | disclosed |
| WO-2009144394-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | APP 1746/4885NPC1 3575/4885RAB9A 798/4885 |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | SMN1; SMN2, HDAC5, PUM1 | APP 1642/4885NPC1 3169/4885RAB9A 643/4885 |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | APP 4885/4885NPC1 4434/4885RAB9A 3570/4885 |
| US-20140107073-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | APP 2479/4885NPC1 1770/4885RAB9A 900/4885 |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | HRH3, H1-3, HRH4 | APP 4293/4885NPC1 1717/4885RAB9A 763/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | APP 4885/4885NPC1 4434/4885RAB9A 3570/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | APP 4885/4885NPC1 4434/4885RAB9A 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.